Brief: Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% For Presbyopia
05/09/2024 13:08
Sept 5 (Reuters) - Ocuphire Pharma Inc OCUP.O :
* OCUPHIRE PHARMA INITIATES VEGA-3 PHASE 3 TRIAL EVALUATING
PHENTOLAMINE OPHTHALMIC SOLUTION 0.75% FOR PRESBYOPIA
* OCUPHIRE PHARMA INC - TOP-LINE DATA FROM VEGA-3 PHASE 3
TRIAL
EXPECTED H1 2025
* OCUPHIRE PHARMA INC - TOP-LINE DATA FROM LYNX-2 PHASE 3
TRIAL
EXPECTED Q1 2025
Source text for Eikon: ID:nGNXbY4fsS
Further company coverage: OCUP.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on Opus Genetics
See all newsUS RESEARCH ROUNDUP-Affiliated Managers Group, Goldman Sachs, Vaxcyte
Health Rounds: Experimental eye drops ease night vision problems for drivers
U.S. STOCKS ON THE MOVE-Apple, Omnicom, Jersey Mike's Subs
U.S. STOCKS ON THE MOVE-Airbnb, Lyft, Korn Ferry
Opus Genetics hits 5-year high on positive early- to mid-stage eye disease gene therapy data